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3ABSTRACT
Background
Despite previous identification of pre-operative clinical and radiological predictors of post-
operative paediatric cerebellar mutism syndrome (CMS), a unifying pre-operative risk
stratification model for use during surgical consent is currently lacking. The aim of the
project is to develop a simple imaging-based pre-operative risk scoring scheme to stratify
patients in terms of post-operative CMS risk.
Methods
Pre-operative radiological features were recorded for a retrospectively assembled cohort of
89 posterior fossa tumour patients from two major UK treatment centers (age 2-23yrs; gender
28M,61F; diagnosis: 38 pilocytic astrocytoma, 32 medulloblastoma, 12 ependymoma, 1 high
grade glioma, 1 pilomyxoid astrocytoma, 1 atypical teratoid rhabdoid tumour, 1 hemangioma,
1 neurilemmoma, 2 oligodendroglioma). Twenty-six (29%) developed post-operative CMS.
Based upon results from univariate analysis and C4.5 decision tree, stepwise logistic
regression was used to develop the optimal model and generate risk scores.
Results
Univariate analysis identified five significant risk factors and C4.5 decision tree analysis
identified six predictors. Variables included in the final model are MRI primary location,
bilateral middle cerebellar peduncle involvement (invasion and/or compression), dentate
nucleus invasion and age at imaging > 12.4 years. This model has an accuracy of 88.8%
(79/89). Using risk score cut-off of 203 and 238, respectively, allowed discrimination into
low (38/89, predicted CMS probability < 3%), intermediate (17/89, predicted CMS
probability 3-52%) and high-risk (34/89, predicted CMS probability ≥ 52%).   
4Conclusions
A risk stratification model for post-operative paediatric CMS could flag patients at increased
or reduced risk pre-operatively which may influence strategies for surgical treatment of
cerebellar tumours. Following future testing and prospective validation, this risk scoring
scheme will be proposed for use during the surgical consenting process.
[Word count 270/300]
5INTRODUCTION
Post-operative paediatric cerebellar mutism syndrome (CMS) (1) is characterized by mutism
or reduced speech and emotional lability following cerebellar or 4th ventricle tumour surgery
in children. Motor features such as hypotonia, ataxia and neurobehavioral disturbances are
commonly associated. There is typically a latent period of 2-5 days between surgery and the
onset of the syndrome. Recovery of mutism occurs over weeks to months, but the majority of
affected patients have persistently reduced processing speeds with global impact including
worse cognitive outcomes than comparable patients without CMS, and are frequently left
with persistent motor and non-motor speech disorder (2, 3). The estimated incidence of CMS
following paediatric posterior fossa surgery is 11-29% (4).
Providing accurate risk information regarding surgical procedures to the patient and their
family is central to the process of seeking informed consent (5). Primary surgery in
cerebellar tumours is directed at controlling raised intra-cranial pressure, obtaining a tissue
diagnosis and debulking of tumour. However, the overall range of incidences of CMS quoted
in the literature do not permit patient specific risks to be estimated, although previous reports
have suggested that tumour type (histological and molecular), anatomical location and patient
characteristics may have an influence (see Table 1) (6-18). Not all of this information, such
as the tumour type or structures damaged during surgery, will be known preoperatively. For
example the risk model for the development of CMS proposed by Law et al included
determination of tumour pathology in the predictive model (15), although it should be noted
that this predictive model was not intended to be used as a pre-surgical risk scoring tool.
These factors are relevant because if a constellation of pre-operative features could be
identified to confer either an estimated very low risk or higher CMS risk estimate for
6individuals this would have important clinical implication for approaches to surgery. For the
surgeon knowing the risk was low (<10%) for the individual case would reinforce their
confidence in established surgical approaches. Where the risk was moderate or high new
approaches to primary surgery could be explored in risk adjusted clinical trials. For the
parent or patient their personal understanding of risk would be enhanced. Where the risk was
low, this would enhance confidence and support consent to the current approaches to primary
surgery, where the risk was moderate or high, it would support the informed consent process
within risk-adjusted trials of new approaches to primary surgery.
(Insert Table 1 here).
Based on the identified lack of a validated pre-operative risk stratification models for use
during surgical consent, we performed a retrospective analysis of pre-operative clinical and
imaging data to develop an imaging-based risk stratification tool to be applied prospectively.
To do this we used data from paediatric posterior fossa tumour cohorts from two major UK
treatment centers. The aim of the analysis is to develop a simple risk scoring system that
allows stratification of patients into low, intermediate and high risk groups for development
of CMS.
MATERIALS AND METHODS
Study population
The study population consists of two UK patient cohorts from Nottingham and Liverpool
which were assembled retrospectively in a similar way: Nottingham patients were identified
from a locally-held database of children who had undergone resection of posterior fossa
tumour at Nottingham University Hospital NHS Trust between June 2006 and October 2013.
7The Liverpool cohort included all children who underwent posterior fossa surgery for tumour
resection at Alder Hey Children’s NHS Foundation Trust between June 2007 and October
2012 and had follow up MRI imaging for at least one year.
Exclusion criteria included patients without complete and available pre-operative scans;
patients lacking CMS outcome assessment data; patients who had already undergone partial
resection or chemotherapy; patients younger than two years for whom establishing a
diagnosis of CMS is difficult due to the limited language development in this group.
Post-operative CMS status and patient factors
For included cases, post-operative CMS status, defined as markedly reduced or absent
speech, was ascertained from clinical notes using a standardized pro-forma. For Nottingham
patients, CMS onset and subsequent duration of CMS at any point post-operatively were
recorded. Alder Hey recorded decreased speech output at day seven, reasoning that this
would minimize confounding post-operative factors causing mutism. Additional patient data
including age at surgical resection and sex were recorded. These assessments were conducted
separately in within the institutions and were not defined prospectively between institutions.
The methods and allocation of mutism status were subsequently compared and validated
between investigators (DAW, RK) where it was agreed that the case selection processes were
identifying the same features. At this time the consensus definition of CMS had not been
agreed or published (1); this experience subsequently informed that consensus process.
Image analysis
8Based on prior literature and the hypothesized mechanism of CMS, imaging features were
prospectively defined (Table 2). A single experienced paediatric neuroradiologist (RD)
recorded the presence or absence of these imaging features on all cases, blinded to clinical
status or clinical outcome, using the data collection form shown in the appendix. In addition,
the paediatric neuroradiologist was asked to record tumour size, hydrocephalus based on
Evans’ index, primary tumour location and their radiological diagnosis of tumour type based
solely on pre-operative imaging features.
(Insert Table 2 here)
A second experienced paediatric neuroradiologist (SA) performed an identical evaluation of
the imaging data from 20 patients (10 from the Nottingham cohort and 10 from the Liverpool
cohort) to allow an assessment of inter-observer agreement of all imaging variables between
the radiologists.
Statistical analysis
In view of the long list of imaging features, a combined approach was used for initial variable
selection. Descriptive analysis was used to characterize the study population. T-test, Mann–
Whitney U test, Chi-square or Fisher’s exact test were used for comparison between groups
as appropriate and odds ratios (ORs) with 95% confidence intervals were calculated for each
variable using logistic regression to identify potential predictors of post-operative CMS.
Potential predictors were also incorporated into the C4.5 Decision Tree Classifier (C4.5) (19)
to reproduce the classification into CMS status (Yes/No). C4.5 uses the concept of
information gain to generate a visual decision tree or sets of if-then rules that can be easily
9followed and interpreted. It is also a way to reduce the number of variables in the study, as it
highlights those variables that play an important role in identifying the outcome. Different
scenarios using raw or recoded data were considered to search for the run with the highest
overall accuracy and least number of CMS cases misclassified as non-mute (false negative).
Variables reaching significance (p<0.05) in univariate analysis, together with variables in the
decision tree, were used as the inputs in forward and backward stepwise logistic regression
models.
The optimal model was developed based upon goodness of fit, classification tables of
predicted versus actual group, as well as usefulness in the clinical setting. Multiple logistic
regression coefficients for the predictors selected from the optimal model were multiplied by
10 then rounded off to the nearest integer.
In view of the subjective nature of the image assessment, we further tested the inter-observer
agreement of four imaging variables selected for inclusion in the final model with a group of
experienced paediatric neurosurgeons. These individuals were invited to participate in the
image review at an international meeting of neuro-oncology experts, and the review included
a subset of 12 cases from the combined cohort (6 with CMS, 6 without CMS). Cohen’s
kappa or Fleiss's Kappa was used to evaluate inter-observer variation as appropriate. The K
value was interpreted as follows: < 0.20 = Poor, 0.21 - 0.40 = Fair, 0.41 - 0.60 = Moderate,
0.61 - 0.80 = Good, 0.81 - 1.00 = Very good (20).
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All analyses other than decision trees were performed with IBM SPSS 22.0 for Windows
(IBM Corp. Armonk, NY, USA), and a p < 0.05 was considered statistically significant in all
analyses. The C4.5 decision tree analysis was performed using Weka (21).
Approvals
The data used for the modelling is part of an on-going service evaluation project of existing
clinical case data aiming to evaluate and improve outcomes from posterior fossa tumour
surgery, and according to UK NHS Health Research Authority guidance (22) does not require
Research Ethics Committee (REC) or Institutional Review Board (IRB) approval.
RESULTS
The combined cohort
Ninety-nine patients were initially identified based on the inclusion criteria (51 from
Nottingham and 48 from Liverpool). Patients who had no pre-operative scan for review
(n=8, no CMS events) and aged under two (n=2, no CMS event) were excluded subsequently.
The distribution of age, gender, tumour location, radiological diagnosis, diagnosis, and post-
operative CMS rate were examined before data merging (Table S1). There were more
ependymoma and less medulloblastoma cases in the Liverpool cohort. No significant
difference was observed in other variables between the two patient cohorts.
The combined cohort for analysis therefore consists of 89 patients (28 males and 61 females),
age ranged from 2 to 23 years. The most common tumour diagnosis was pilocytic
astrocytoma (n=38; 43%), followed by medulloblastoma (n=32; 36%), ependymoma (n=12;
13%), atypical teratoid rhabdoid tumour (n=1; 1%), hemangioma (n=1; 1%), neurilemmoma
(n=1; 1%) and oligodendroglioma (n=2; 2%). As for tumour location, about 45% of the
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patients had tumours in the fourth ventricle (n=40), 37% in cerebellar hemisphere (n=33),
13% in vermis (n=12) and 5% had tumours at multiple sites (n=4).
(Insert Table S1 here)
Post-operative CMS event rate
Twenty-six of 89 patients (29%) developed post-operative CMS; the distribution of their age,
gender and MRI imaging features are summarized in Table 3 (data reported as column
percentage). Subgroups with high post-operative CMS event rate (Table S2, row percentage
50% or higher) were found to have bilateral middle cerebellar peduncle (MCP) invasion
(100%, 4/4), bilateral dentate nucleus (DN) invasion (69%, 9/13), bilateral MCP compression
(67%, 10/15), fourth ventricular location (53%, 21/40) or multi-sites (50%, 2/4), and bilateral
superior cerebellar peduncle (SCP) invasion (50%, 2/4). No event was observed in cerebellar
hemispheric (CH) tumours (0/33).
(Insert Table 3 and Table S2 here)
Initial variable selection
There were five variables showing significant risk (p<0.05) in univariate analysis: tumours at
fourth ventricle (OR 9.7, 95% CI 3.2-29.6), invaded to fourth ventricle (OR 9.6, 95% CI 2.6-
35.2), followed by brainstem invasion, radiological diagnosis of medulloblastoma and
superior cerebellar peduncle invasion with odds ratios ranged from 3.2-3.5 (Table 4). On the
other hand, tumour at cerebellar hemispheric location showed a strong protective effect; no
patient developed CMS in this subgroup. Lowering the significance level to p=0.1 did not
change the results further, since no other variables showed borderline significance (data not
12
shown).
As for supervised machine learning, the model showed the highest accuracy is shown in
Figure 1. The six predictors this model selected are: CH invasion, bilateral MCP invasion,
DN invasion, MCP compression, preoperative radiological diagnosis of ependymoma and age
at imaging (greater than 12.4 years). This model has an overall accuracy of 91% and
misclassified only 2 out of the 59 patients predicted non-mute.
(Insert Table 4 and Figure 1 here)
Consideration of inter-observer agreement
Inter-observer agreement between two neuroradiologists for the 20 double-reviewed cases
ranged from 0.32-0.69 on tumour invasion and 0.15-0.77 on tumour compression (Table S3).
The agreement was good (ƙ 0.61-0.80) on fourth ventricle compression, fourth ventricle 
invasion, midbrain invasion; moderate (ƙ 0.41-0.6) on vermis invasion, DN invasion, SCP 
invasion, MCP invasion, brainstem invasion, brainstem compression and vermis
compression; fair (ƙ 0.21-0.4) on SCP compression, midbrain compression and cerebellar 
hemisphere (CH) invasion; and poor (ƙ ≤ 0.2) on MCP compression and CH compression. 
(Insert Table S3 here)
Five neurosurgeons were also invited to review a separate subset of 12 patients and scored on
the four selected imaging variables and give their feedback. Kappa statistics for inter-
observer agreement amongst neurosurgeons, ranked from high to low, were: CH invasion 0.5,
MCP compression 0.45, DN invasion 0.3 and MCP invasion 0.28. Although we cannot
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compare kappa from the two series directly, we note that potential users (neuroradiologists
and neurosurgeons) do not have good agreement on MCP compression. Neurosurgeons also
commented that it was difficult to decide whether MCP was invaded or just compressed by
tumour. We therefore decided to recode MCP invasion and compression into a single
variable ‘MCP invasion and/or compression’ (ƙ =0.50 amongst neurosurgeons) and included 
this variable in the subsequent multivariate analysis.
Final model and risk scores
Age at imaging (greater or less than 12.4 years), MRI tumour location, radiological diagnosis,
together with all imaging features identified from the two methods were used as inputs for
stepwise logistic regression to structure the optimal model. MCP invasion and MCP
compression were replaced with the new variable ‘MCP invasion and/or compression’.
Cerebellar hemispheric location was also included as a potential protective factor.
All models returned by forward and backward stepwise regression were reviewed. The
model showed the highest accuracy and the least number of false negative cases consists of
the following predictors: cerebellar hemispheric location (p<0.001), cerebellar hemisphere
invasion (p=0.007), bilateral MCP invasion and/or compression (p=0.006), any DN invasion
(p=0.01) and age at imaging > 12.4 years (p=0.027).
This optimal model (Table 5) has an accuracy of 88.8% (79/89), with a sensitivity of 96.2%
(25/26) and specificity of 85.7% (54/63). Multiple logistic regression coefficients for the
predictors were multiplied by 10 then rounded off to the nearest integer (insert Table 5 here).
For the ease of clinical interpretation, cerebellar hemispheric location and CH invasion were
combined into three subgroups to describe primary tumour location: cerebellar hemispheric
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location (risk score =0), midline/non-CH sites with no CH invasion (risk score =218), and
midline/non-CH sites with CH invasion (risk score =183). Risk scores assigned to other risk
factors ranged from 20 (DN invasion, age at imaging greater than 12.4 years) to 23 (bilateral
MCP invasion and/or involvement).
Patient’s total risk score ranged from 0-281, with a greater number being associated with
increased predicted risk of CMS. Using risk score cut-offs 203 and 238 permit discrimination
into low (38/89, predicted probability < 3%), intermediate (17/89, predicted probability 3-
52%) and high-risk (34/89, predicted probability ≥ 52%), respectively.   
(Insert Figure 2 here)
DISCUSSION
An imaging-based risk stratification model for identifying patients at increased risk of post-
operative CMS based on pre-operative features has been developed. Unlike a previously
proposed model (15), this scoring system is based purely on information available pre-
operatively. Following future testing and prospective validation, this risk stratification model
is proposed as an adjunct to the surgical consenting process, providing information to patients
and their parents / carers in a form that is easy to understand with low (<10%), intermediate
and high (>50%) risk groups. Furthermore, if validated in multiple clinical settings this
model may influence surgical decision making and treatment strategies for cerebellar
tumours. A larger multicenter retrospective validation of this model using data from
European and North American centres is currently underway.
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Pre-operative estimation of a high risk of mutism, particularly at the level that it is more
likely to occur than not, if a complete resection is attempted, has implications not just to the
extent to which this needs to be discussed in appropriate consenting for surgery but to the
surgical strategy itself. Increasingly detailed pre-operative imaging and technical advances
with operating microscopes, image guidance systems and ultrasonic surgical aspirators have
driven neurosurgeons to attempting complete resection of tumours more often in recent years.
Korah and colleagues (13) noted when comparing two eras in their medulloblastoma practice
(1990-2000 and 2001–2007) that as the number of patients achieving a complete resection
rose from 77% to 94%, the rate of posterior fossa syndrome more than doubled from 17% to
39% and they found absence of radiographic residuum to be a significant predictor of PFS
development. Over a similar timescale there have been substantial advances in the
understanding of the biology of paediatric brain tumours and medulloblastoma, in particular,
such that for many patients cure of the tumour is now a very realistic option, even if there is
macroscopic residual tumour left behind at the end of operation.
Neuro-oncology multidisciplinary teams will recognize the potential benefit of having a
patient who is clinically in good condition early after surgery and able to progress on to
having adjuvant therapy quickly as opposed to one who has undergone a complete resection
but is unfit to proceed to prompt follow on radiotherapy due to the profound physical,
cognitive and communication difficulties inherent in post-operative paediatric cerebellar
mutism syndrome. Furthermore, the potentially permanent consequences for cognitive,
physical and communication problems can be a high price to pay for cure. The highest risk
patients, with predictive medulloblastoma histology, might well benefit from intentional
subtotal resection or a 2-stage surgical strategy using debulking chemotherapy.
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Increasingly, discussions amongst paediatric neurosurgeons suggest that we may be on the
brink of an era of less aggressive surgery for selected medulloblastoma patients, just as there
has been realization and then widespread acceptance in the last 20 years of the wisdom of a
more conservative approach to surgery in craniopharyngioma in children (23). In addition to
potentially impacting on the consenting process and surgical strategy, in the future a validated
CMS risk score may be also be useful in selecting patients for neuroprotective therapies prior
to the emergence of CMS once these have been developed.
The prevailing anatomo-pathological model for the development of CMS is of damage to the
proximal dentatothalamic pathway, particularly of the dentate nuclei and SCP (4, 17, 24). It
is therefore unsurprising that dentate invasion and fourth ventricular location, which would
increase the likelihood of dentate or SCP injury, were variables retained in the final model.
SCP invasion was identified as a risk factor in the univariate analysis, but was not retained in
the final model, whereas involvement of the MCPs was included in the final model. The
MCPs are the major afferent pathway to the cerebellum but do not contribute to the
dentatothalamic pathway. It is possible that the MCPs have a previously unrecognized direct
role in the pathophysiology of CMS, but this association may simply reflect predominance of
fourth ventricular tumours in the CMS group.
Dentate nucleus invasion was included in the final model as a binary variable (invasion
Yes/No) rather than three categories (none, unilateral, bilateral). We explored a model which
DN was entered as three categories, finding that both unilateral and bilateral invasion showed
increased risk after adjustment for other risk factors (adjusted OR 9.9, 95% CI 1.5 – 65.6 and
5.2, 95% CI 0.8 – 33.1 for unilateral and bilateral invasion respectively). Given the small
sample size of each stratum, the number of variables fitted in the model and the broad and
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largely overlapping confidence intervals, we decided to go with binary (invasion Yes/No)
cut-off in the final model.
An unexpected variable retained in our final model was that age > 12.4 years was predictive
of CMS risk. This is in spite of previous studies observing either no age association or
younger age as a risk factor for CMS. Of note, the incidence of CMS was not actually higher
in the older age groups (highest in 5-9 year olds). We cannot rule out the possibility that age
over 12.4 years is closely associated with another risk factor which was not measured or
picked up by our analysis, or it could be by chance. This will require confirmation in further
validation studies. Similarly the finding that radiological diagnosis of probable ependymoma
conferred lower risk in the decision tree analysis would not have been expected based on
existing literature, but this feature was not retained in the final model.
In conducting this study, we have taken a number of steps to minimize bias. The patient data
used in this study were unselected consecutive cases from two large and representative
paediatric neurosurgery centers in the UK. Definitions of post-operative mutism were
consistent across the two cohorts. A number of imaging features were assessed on scans, the
choice of which was based on prior literature and current putative anatomical models of
CMS. Images from all participants were centrally reviewed using standardized definitions
and imaging data capture pro-forma, and inter-observer reliability was assessed for
identification of these imaging features. In our statistical analysis we used univariate analysis
as well as decision tree analysis to screen for the most important predictors for CMS and to
identify the relevant cut points.
We acknowledge a number of important limitations to this work. Firstly, many of the
imaging features evaluated on the scans are subjective, which was reflected in the relatively
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poor inter-observer agreement for some of the features. In particular, during the evaluation
we often found it difficult to decide whether a structure was invaded by tumour, or just
compressed. We found that, for certain anatomical sites, recoding the individual invasion and
compression variables into a single variable (i.e. invasion and / or compression) improved
inter-observer variation, and in the case of the MCP, the composite variable invasion and / or
compression was included in the final model. Nonetheless, we are aware that the subjective
nature of the evaluation, despite the clear neuroanatomical definitions, will be a source of
concern. For this reason, the tool requires wider testing and prospective evaluation, and may
require further refinements and formal training in the application of consistent
neuroanatomical definitions.
We also acknowledge that the sample size is relatively small, and that the predictive value of
the tool could be skewed by local surgical practice and outcomes at the two centers that
contributed data. We also note that our combined cohort had no CMS event in patients with
tumours centered in the cerebellar hemisphere whereas other studies have observed CMS in
patients with cerebellar hemisphere tumours. Our retrospective dataset did not include
handedness data, which is a potential weakness as handedness has previously been related to
CMS incidence. We did not have outcome data regarding severity of CMS, and so while our
risk score allows prediction of incidence of CMS, it cannot predict severity.
The motivation for the development of this risk model was to identify those at the highest risk
of mutism to assist the surgeon in strategy selection to reduce the incidence of this
devastating condition. The assumption that more anatomical features were associated with
greater risk drove the analysis. The model supports this view to a significant degree. An
alternative approach aimed at identifying those at least risk was not considered until after the
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model had been developed. This approach may have significant merit as it would offer the
surgeon and parent partnership greater confidence to adopt established techniques for primary
surgery in low risk cases and support informed consent processes for novel approaches to
surgery in moderate and high risk cases. Overall our intention was highlight the risk of CMS
as a complication of posterior fossa tumour surgery in order to reduce its incidence overall,
given the devastating consequences for the children and their families post surgery and the
long term consequences for survivors and their adult lives.
CONCLUSIONS
A risk stratification model for post-operative CMS could flag patients at increased risk pre-
operatively and may influence strategies for surgical treatment of cerebellar tumours.
Following future testing and prospective validation in a larger multicenter collaboration, this
risk scoring scheme may be further developed and utilized during the surgical consenting
process and influence future trial design in astrocytoma and medulloblastoma in particular.
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Table 1. Summary of published studies that report statistical associations between clinical and structural imaging findings and development of
post-operative pediatric cerebellar mutism syndrome.
Paper Target
condition
Study Population Preoperative Factors Postoperative
Surgical purpose,
age range*, gender
CMS rate
(CMS/Total)
Significant risk factors Other variables considered Significant risk factors Other variables considered
Catsman-
Berrevoets
et al, 1999
(6)
Cerebellar
mutism and
subsequent
dysarthria
(MSD)
CTR, 2-17yrs.
29m 13f
28.6%
(12/42)
Cerebellar midline
location (OR=8.2,
p=0.004).
Patient Age, Gender, Tumor
size, Hydrocephalus
MB pathology (p=0.006),
Vermian incision (vs lateral)
(p=0.028).
Tumor size in
medulloblastoma group
(1cm increment OR=1.76,
p=0.05)
Postoperative infection,
Hydrocephalus
Doxey et al,
1999 (7)
PFS PFTR. 7.9%
(20/253)
Brainstem invasion
(p<0.05)
Not stated Tumor histology (p<0.05) Not stated
Ersahin et
al, 2002 (8)
CMS PFTR. 3-11yrs.
6m 5f.
27.3% (3/11) Not stated Age, Gender, Tumor size,
Tumor location, Hydrocephalus
Brainstem
involvement/clinical signs of
brain stem injury after
surgery (p=0.003)
Tumor histology, Vermian
incision, SPECT
abnormalities
Robertson
et al, 2006
(9)
CMS PFTR.
277m 273f
23.8%
(107/450)
Brainstem invasion
(p=0.003) and non-
cerebellar hemisphere
location (p=0.002).
Age at diagnosis, Gender,
Tumor location (except
cerebellar hemisphere)
CNS infection (p=0.024) >90% resection, CSF leak,
Aseptic meningitis
Kotil et al,
2008 (10)
CMS CTR. 3-13yrs.
19m 13f.
31.3%
(10/32)
Midline tumor location
(OR=6.7, p<0.003)
Not stated MB histology†, Vermian
incision†.
Tumor size in
medulloblastoma group
(1cm increment OR=1.53,
p=0.04)
Not stated
McMillan
et al, 2009
(11)
CMS PFTR. 1.8-15.8yrs.
30m 21f.
25.5%
(13/51)
Pons anteroposterior
diameter (p<0.05)
Age at mutism onset,
Maximum Tumor dimensions,
Tumor volume
Change in pons
anteroposterior diameter
following surgery (p<0.005)
Vermian incision, Surgical
approach taken, Surgical
shunt, Pons anteroposterior
diameter, Tumor angle.
Paper Target
condition
Study Population Preoperative Factors Postoperative
Surgical purpose,
age range*, gender
CMS rate
(CMS/Total)
Significant risk factors Other variables considered Significant risk factors Other variables considered
Wells et al,
2010 (12)
CMS PFTR.
Mean age 6.19
(CMS) and 7.05
(non-CMS). 13m
15f.
39.3%
(11/28)
Brainstem invasion
(p<0.05)
Age at diagnosis, Gender,
Tumor size, Tumor location,
Hydrocephalus, Peritumoural
edema, Involvement of
Cerebellar medullary angle or
Cerebellopontine angle
Not stated Edema of cerebellar
hemispheres, Brainstem,
Dentate nuclei, MCP
(p=0.051) or SCPs
(p=0.074), Vermian incision,
Extraventricular drain use,
Total resection.
Korah et al,
2010 (13)
PFS MB resection.
>3 yrs (median
8.2yrs).
43m 21f.
28.6%
(18/63)
Univariate: Younger age
(p=0.018), Midline tumor
location (p=0.025),
Brainstem invasion
(p<0.001)
Multivariate: Younger age
(p=0.027)
Not stated Univariate: Absence of
radiographic residual tumor
(p=0.049)
Multivariate: Absence of
radiographic residual tumor
(p=0.042)
Vermian incision
Kupeli et al,
2011 (14)
PFS PFTR. <16yrs. 21m
15f.
25.0% (9/36) Univariate: Midline tumor
location (p=0.05), Low
socioeconomic level
(p=0.06)
Multivariate: Midline
tumor location (OR=6.7,
95%CI 1.2-37.5); low
socioeconomic level
(OR=5.7, 95% CI 1.0-
32.0)
Patient Age, Gender, Tumor
Size, Hydrocephalus, Spinal
seeding
Univariate: MB histology
(p=0.05)
Multivariate: MB (OR=7.2,
95% CI 1.0-54.0)
Suboccipital craniotomy,
Gross-total resection,
Existence of shunt, Residual
disease, Edema
Law et al,
2012 (15)
CMS PFTR. 5-17yrs.
Case-control study:
17 CMS patients
(7m 10f), 34 non-
CMS patients (21m
13f) and 28 healthy
controls (14m 14f)
Not
applicable
Univariate: Left-
handedness (p=0.004),
Larger tumor size
(p=0.037).
Multivariate: Left
handedness p=0.02
Age at diagnosis, Tumor
location
MB histology (p=0.02) Extent of resection
Paper Target
condition
Study Population Preoperative Factors Postoperative
Surgical purpose,
age range*, gender
CMS rate
(CMS/Total)
Significant risk factors Other variables considered Significant risk factors Other variables considered
Siffert et al,
2000 (16)
CMS PFTR. 3-12yrs. 8m
8f.
Matched case-
control study: 8
CMS cases (4m 4f)
and 8 age, sex,
tumour location and
operative procedure
matched non-CMS
controls.
Not
applicable
Not stated Not stated Not stated Complete resection
Morris et al,
2009 (17)
PFS PFTR. <21yrs. 16m
10f
Case-control study:
10 PFS patients
(10m 0f) and 13
controls (6m 7f)
randomly selected
from 49 non-CMS
patients
Entire study
cohort 21%
(13/64)
More rostral position in
fourth ventricle (p=0.035)
Uni- or bi-lateral Cerebellar
hemisphere, Dentate nuclei,
ICP, MCP, SCP, Medulla,
Pons, Thalamic or Cerebral
hemisphere involvement
(judged by T2w), Splay
between SCP, Hydrocephalus.
Uni- or bi-lateral Pons
(p=0.029), Midbrain
(p=0.003) and SCP
(p=0.008) involvement
(judged by T2w on
immediate postop)
Uni- or bi-lateral Cerebellar
hemisphere, Dentate nuclei,
ICP, MCP, Medulla or
Thalamic involvement
(judged by T2w)
Miller et al,
2010 (18)
PFS PFTR. 3-11yrs.
Matched case-
control study: 11
PFS patients and 11
age, gender matched
non-PFS controls
Not
applicable
NS NS Bilateral damage to the
proximal efferent cerebellar
pathway (OR=12, 95%
CI1.12-129)
† Statistics not provided but stated to be significant in the text.
KEY: CMS: Cerebellar mutism syndrome, PFS: Posterior fossa syndrome, CTR: Cerebellar tumor resection, PFTR: Posterior fossa tumor resection, MB:
Medulloblastoma, SCP: Superior cerebellar peduncle, MCP: Middle cerebellar peduncle, ICP: Inferior cerebellar peduncle.
Table 2. Definition of imaging features – tumor invasion and compression
Anatomical Site Definition
Vermis Tumor invasion Either tumor arises from vermis, or if tumor adjacent to vermis then
there is a lack of distinction between tumor and vermis.
Tumor compression Compression of vermis with distortion of normal vermian
configuration including effacement of vermian sulci and / or and
marked dorsal or lateral shift. Displacement of vermis alone without
other features does not qualify.
Cerebellar
hemisphere (CH)
Tumor invasion Either tumor arises from cerebellar hemisphere (CH), or when the
tumor is primarily located in midline sites (4th ventricle, cerebellar
vermis) or other non-cerebellar hemispheric sites and extends into /
invades the cerebellar hemisphere beyond the dentate nucleus or
middle cerebellar peduncle
Tumor compression Compression of CH with distortion of normal CH configuration
including effacement of ipsilateral cerebellar sulci and ipsilateral
subarachnoid spaces.
Fourth ventricle Tumor invasion Either tumor arises within fourth ventricle, or if tumor adjacent to
fourth ventricle then tumor extends to involve the wall of the fourth
ventricle, with or without tumor nodule or seeding of tumor within
the fourth ventricle.
Tumor compression Effacement of fourth ventricle by extrinsic tumor.
Brainstem Tumor invasion Tumor in a location adjacent to the brainstem for which there is no
clear distinction between the tumor and parenchyma of the
brainstem.
Tumor compression Compression of brainstem with distortion of normal brainstem
configuration, with AP flattening of the brainstem against the clivus,
loss of the ventral pontomedullary indentation and effacement of
the prepontine or medullary cisterns (depending on tumor location).
Displacement of brainstem alone without other features does not
qualify.
Midbrain Tumor invasion Tumor involving superior parts of cerebellum or fourth ventricles for
which there is no clear distinction between the tumor and
parenchyma of the midbrain. Example also includes brainstem
invasion.
Tumor compression Compression of midbrain with distortion of normal midbrain
configuration, with AP flattening and splaying of the ventral
midbrain and superior / dorsal displacement of the tectum.
Displacement of midbrain alone without other features does not
qualify.
Middle
cerebellar
peduncle (MCP)
Tumor invasion When tumor clearly invades the MCPs bilaterally or where the
interface between tumor and MCPs is indistinct such that MCP
invasion is thought possible.
Tumor compression MCP markedly distorted by the tumor mass, with dorso-ventral
thinning of the MCP. Displacement of MCP alone without other
features does not qualify,
Superior
cerebellar
peduncle (SCP)
Tumor invasion Either tumor arises from SCP, or if tumor adjacent to SCP then there
is a lack of distinction between tumor and SCP.
Tumor compression Compression of SCP with distortion of normal SCP configuration
including marked thinning or elongation of the SCP.
Dentate Nucleus
(DN)
Tumor invasion Abnormal signal extends into the region of the dentate nucleus, with
indistinct boundary between the tumor and site of the dentate
nucleus
Table 3. Distribution of age, gender, radiological diagnosis, MRI tumor location and imaging
features by post-operative CMS status.
Post-operative CMS
Total Yes (n=26) No (n=63)
n Col% n Col% n Col% p-value
Age
Mean±SD 9.7±5.0 9.4 ± 4.7 9.8 ± 5.2 0.709
Median (IQR) 8.9 (8.4) 8.0 (14.7) 9.4 (9.1) 0.691
Gender 0.802
Male 28 31% 9 35% 19 30%
Female 61 69% 17 65% 44 70%
Pre-operative radiological diagnosis 0.004
Ependymoma 12 13% 4 15% 8 13%
Medulloblastoma 36 40% 16 62% 20 32%
Pilocytic astrocytoma 40 45% 5 19% 35 56%
Other 1 1% 1 4% 0 0%
MRI tumor location <0.001
Vermis 12 13% 3 12% 9 14%
Cerebellar hemisphere 33 37% 0 0% 33 52%
Fourth ventricle 40 45% 21 81% 19 30%
Other or multi-sites 4 4% 2 8% 2 3%
MRI image analysis
MRI Hydrocephalus
Evans’ Index > 0.3 59 66% 16 62% 43 68% 0.542
Tumor invasion
Vermis 47 53% 17 65% 30 48% 0.127
Cerebellar hemisphere 42 47% 1 4% 41 65% <0.001
Brainstem 39 44% 17 65% 22 35% 0.008
Midbrain 12 13% 4 15% 8 13% 0.741
Middle cerebellar peduncle 44 49% 13 50% 31 49% 0.946
Superior cerebellar peduncle 31 35% 14 54% 17 27% 0.016
Dentate nuclei 49 55% 16 62% 33 52% 0.430
Fourth ventricle 51 57% 23 88% 28 44% <0.001
Tumor compression
Vermis 72 81% 21 81% 51 81% 0.999
Cerebellar hemisphere 48 54% 7 27% 41 65% 0.001
Brainstem 45 51% 14 54% 31 49% 0.691
Midbrain 27 30% 8 31% 19 30% 0.955
Middle cerebellar peduncle 51 57% 13 50% 38 60% 0.371
Superior cerebellar peduncle 70 79% 21 81% 49 78% 0.754
Fourth ventricle 77 87% 24 92% 53 84% 0.497
Table 4 Crude odds ratio (OR) and 95% confidence interval of the five risk factors reached
significant level in univariate analysis, ranked by effect size
Total
(n=89
)
Post-operative CMS
Crude OR
(95% CI)
Yes (n=26) No (n=63)
n n Col% n Col%
MRI tumor location: fourth ventricle 40 21 81% 19 30% 9.7 (3.2-29.6)
Tumor invasion: fourth ventricle 51 23 89% 28 44% 9.6 (2.6-35.2)
Tumor invasion: brainstem 39 17 65% 22 35% 3.5 (1.3-9.2)
Radiological diagnosis: medulloblastoma 36 16 62% 20 32% 3.4 (1.3-8.9)
Tumor invasion: SCP* 31 14 54% 17 27% 3.2 (1.2-8.2)
*SCP: superior cerebellar peduncle
Table 5. Variables in the risk prediction model and risk score
Predictors Regression
coefficient
Adjusted OR
(95% CI)*
Risk
Score
MRI primary location
Cerebellar hemisphere, CH invasion (+) ^
Midline/other non-CH sites, CH invasion (-)
Midline/other non-CH sites, CH invasion (+)
-
21.76
18.26
1.0
--
--
0
218
183
Bilateral MCP invasion and/or compression 2.30 10.0 (1.9-51.6) 23
DN invasion 1.98 7.2 (1.6-32.7) 20
Age at imaging > 12.4 yrs 1.96 7.1 (1.2-39.9) 20
^ no CMS event. *Adjusted for all variables included in the model
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Figure 1. C4.5 decision tree with the highest accuracy (91.0%, 81/89). Predictors identified were CH invasion, bilateral MCP invasion,
DN invasion, pre-operative radiological diagnosis of ependymoma, MCP compression, and age.
Minimum number of objects in last layer =4
Accuracy = 91% (81/89)
0.5% 3%
13%
19%
25%
52%
60%
88% 92%
99%
0%
20%
40%
60%
80%
100%
0 20 40 183 203 218 223 226 238 241 258 261 281
PR
ED
IC
TE
D
PR
O
BA
BI
LI
TY
RISK SCORE
0
5
10
15
20
25
30
0 20 40 183 203 218 223 226 238 241 258 261 281
FR
EQ
U
EN
CY
RISK SCORE
CMS (+), n=26
CMS (-), n=63
Low risk Intermediate risk High risk
Figure 2. Predicted post-operative CMS probability (top) and distribution of cases (bottom) by risk score
Table S1. Distribution of age, gender, radiological diagnosis, MRI tumor location and post-
operative cerebellar mutism rate of the two cohorts.
Total
(n=89)
Alder Hey
(n=38)
Nottingham
(n=51)
p-valuen Col % n Col % n Col %
Year of surgery 2007-2012 2006-2013
Gender 0.345
Male 28 31% 14 37% 14 27%
Female 61 69% 24 63% 37 73%
Age at pre-operative scan
Mean ± SD (years)
min, Max (years)
9.7±5.0
2.0, 22.9
9.1±4.6
2.1, 17.6
10.2±5.3
2.0, 22.9
0.343
Diagnosis 0.008
Ependymoma 12 13% 9 24% 3 6%
Medulloblastoma 32 36% 8 21% 24 47%
Pilocytic astrocytoma 38 43% 16 42% 22 43%
Other† 7 8 % 5 13% 2 4%
Radiological diagnosis* 0.233
Ependymoma 12 13% 8 21% 4 8%
Medulloblastoma 36 40% 15 39% 21 41%
Pilocytic astrocytoma 40 45% 15 39% 25 49%
Other (non-committal) 1 1% 0 0% 1 2%
MRI primary tumor location* 0.254
Vermis 12 13% 7 18% 5 10%
Cerebellar hemisphere 33 37% 11 29% 22 43%
Fourth ventricle 40 45% 17 45% 23 45%
Post-operative CMS 0.480
Yes 26 29% 13 34% 13 25%
No 63 71% 25 66% 38 75%
*Radiologist’s estimate. † Hemangioma (n=1), Neurilemmoma (n=1), Atypical Teratoid
Rhabdoid Tumour (n=1), Olidodendroglioma (n=2)
Table S2 Post-operative CMS event rate in each stratum
CMS event
Predictor Total N n
event rate
( row %)
Centre
Liverpool 38 13 34%
Nottingham 51 13 26%
Gender
Female 28 9 32%
Male 61 17 28%
Age group
2-4 years 21 4 19%
5-9 years 29 12 41%
10-14 years 23 5 22%
≥ 15 years 16 5 31%
Radiological diagnosis
Pilocytic astrocytoma 40 5 13%
Ependymoma 12 4 33%
Medulloblastoma 36 16 44%
Other 1 1 100%
MRI primary location*
Vermis 12 3 25%
Cerebellar hemisphere 33 0 0%
Fourth ventricle 40 21 53%
Other or multi-sites 4 2 50%
MRI Hydrocephalus
Evan's Index > 0.3 59 16 27%
Tumor invasion
Vermis 47 17 36%
Cerebellar hemisphere 42 1 2%
Brainstem 39 17 44%
Midbrain 12 4 33%
Middle cerebellar peduncle 44 13 30%
unilateral 40 9 23%
bilateral 4 4 100%
Superior cerebellar peduncle 31 14 45%
unilateral 27 12 44%
bilateral 4 2 50%
Dentate nuclei 49 16 33%
unilateral 36 7 19%
bilateral 13 9 69%
Fourth ventricle 51 23 45%
Tumor Compression
Vermis 72 21 29%
Cerebellar hemisphere 48 7 15%
Brainstem 45 14 31%
Midbrain 27 8 30%
Middle cerebellar peduncle 51 13 25%
unilateral 36 3 8%
bilateral 15 10 67%
Superior cerebellar peduncle 70 21 30%
unilateral 31 3 10%
bilateral 39 18 46%
Fourth ventricle 77 24 31%
*Radiologist’s estimate
Table S3. Inter-observer agreement between two neuroradiologists for the 20 doubly-
reviewed cases
Inter-observer agreement (Kappa)
between two radiologists
Anatomical Site Invasion Compression
Vermis 0.60 0.44
Cerebellar hemisphere 0.32 0.15
Brainstem 0.50 0.49
Midbrain 0.64 0.34
Middle Cerebellar peduncle 0.52 0.20
Superior Cerebellar peduncle 0.55 0.38
Dentate Nucleus 0.60 --
Fourth ventricle 0.69 0.77
CMS assessment
 Hospital No: _____________________
 Date of birth (DD/MM/YYYY): / /
 Age: _____________________
 Date of surgery (DD/MM/YYYY): / /
 Gender: Male Female
 CMS details:
Nottingham
- Mutism: No Yes
- Latency (days): _____________________
- Duration (days): ____________________
- Date patient first spoke (DD/MM/YYYY): / /
- Last review (DD/MM/YYYY): / /
- Additional neuropsychological information:
Ataxia
Abnormal tongue movements
Neurobehavioral changes
Alder Hey
- Decreased speech output at day 7 No Yes
- Avolitional at day 7 No Yes
- Disturbed behaviour at day 7 No Yes
- Additional information
o Presence of other confounders (<2 years, obtunded peri-operatively,
decompensated hydrocephalus)
No Yes ________________________________________________
o PFS global severity impression
No Mild Moderate Severe
Imaging data
Patient, DOB and Date of Surgery
1. Hospital number: ________
2. Date of Birth (DD/MM/YYYY): / /
3. Gender: Male Female
4. Date of Pre-op scan (DD/MM/YYYY): / /
5. MRI Hydrocephalus: Evan’s index (e.g., 0.23) ________ binary : No Yes
6. Pathology estimate
Ependymoma
High grade glioma
Medulloblastoma
Pilocytic astrocytoma
Pilomyxoid Astrocytoma
Other ______________
Not known
7. Tumour size (mm): ________ x ________ x ________
8. Primary tumour location
Vermis
Right cerebellar hemisphere
Left cerebellar hemisphere
Fourth ventricle
Multi-sites
Other _______________
Not known
9. Tumour invasion and compression
Invasion Compression
Vermis No Yes No Yes
Cerebellar hemisphere, left No Yes No Yes
Cerebellar hemisphere, right No Yes No Yes
Brainstem No Yes No Yes
Midbrain No Yes No Yes
Fourth ventricle No Yes No Yes
Middle cerebellar peduncle, left No Yes No Yes
Middle cerebellar peduncle, right No Yes No Yes
Superior cerebellar peduncle, left No Yes No Yes
Superior cerebellar peduncle, right No Yes No Yes
Dentate nucleus, left No Yes
Dentate nucleus, right No Yes
